Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Anakinra

Anakinra

Anakinra: A recombinant human interleukin-1 receptor antagonist used to treat rheumatoid arthritis and other inflammatory conditions.
It blocks the inflammatory effects of interleukin-1, a key mediator of the body's responce to infection, injury, and autoimmune disorders.
Anakinra has been shown to reduce symptoms and improve physical function in patients with moderateto-severe rheumatoid arthritis.
It is administrered by daily subcutaneous injection and generally well tolerated, although some patients may experience injection-site reactions or increased risk of infection.

Most cited protocols related to «Anakinra»

1
Ranking Network Meta-Analysis Treatments
One of the advantages of network meta-analysis is that it can provide information about the ranking of all evaluated interventions for the studied outcome [2] (link), [42] (link). Probabilities are often estimated for a treatment being ranked at a specific place (first, second, etc.) according to the outcome.
Ranking of treatments based solely on the probability for each treatment of being the best should be avoided. This is because the probability of being the best does not account for the uncertainty in the relative treatment effects and can spuriously give higher ranks to treatments for which little evidence is available. So-called rankograms and cumulative ranking probability plots have been suggested as a reliable and comprehensive graphical way to present ranking probabilities and their uncertainty [2] (link). A rankogram for a specific treatment j is a plot of the probabilities of assuming each of the possible T ranks (where T is the total number of treatments in the network). The cumulative rankograms present the probabilities that a treatment would be among the n best treatments, where n ranges from one to T. The surface under the cumulative ranking curve (SUCRA), a simple transformation of the mean rank, is used to provide a hierarchy of the treatments and accounts both for the location and the variance of all relative treatment effects [2] (link). The larger the SUCRA value, the better the rank of the treatment.
The mvmeta command can provide ranking probabilities using the option pbest(min|max, all zero). Options min or max specify whether larger or smaller treatment effects define a better treatment, while all and zero specify the estimation of probabilities for all possible ranks including the reference treatment. The estimated probabilities can be stored as additional variables in the dataset by adding the suboption gen()in pbest() and predictive ranking probabilities (the probability that each treatment will be placed in each rank in a future study [39] (link), [40] ) can be estimated with the suboption predict.
Our STATA command sucra produces rankograms and computes SUCRA values using the ranking probabilities (e.g. as estimated with the mvmeta) as input. If prob1 prob2 etc, is a list of variables including all ranking probabilities (one variable per treatment for each possible rank) as derived from mvmeta then typing
. sucra prob*,mvmetaresultsplots the cumulative rankograms for all treatments.
In Figure 7 we present cumulative rankograms for the network of rheumatoid arthritis trials. The SUCRA values provide the hierarchy for the six active treatments; 1.8%, 59.9%, 66.2%, 21.8%, 75.9%, 41%, 83.4% for placebo, abatacept, adalimumab, anakinra, etanercept, infliximab, rituximab respectively. The cumulative rankograms can also be used to compare different models. In Figure 7 we present also the results from a network meta-regression accounting for small-study effects (using the variance of the log-odds ratios as covariate). The graph shows that small-study effects materially alter the relative effectiveness and ranking of treatments and adjustment will put etanercept and anakira in more favourable order compared with rituximab and abatacept respectively. The option compare() in the command sucra can be used to compare two ranking curves.
Chaimani A., Higgins J.P., Mavridis D., Spyridonos P, & Salanti G. (2013). Graphical Tools for Network Meta-Analysis in STATA. PLoS ONE, 8(10), e76654.
Full text: Click here
Publication 2013
Abatacept Adalimumab Anakinra Etanercept Infliximab Placebos Rheumatoid Arthritis Rituximab
2
Systemic Lupus Erythematosus Treatment Protocol
Enrolled patients were required, at a minimum, to meet the following criteria: 1) age ≥ 18 years; 2) a diagnosis of SLE according to the revised American College of Rheumatology criteria (22 (link)); 3) active disease (SELENA-SLEDAI score ≥ 6) at screening (18 (link)); and 4) seropositivity as defined by 2 positive ANA or anti-dsDNA test results (ANA titers ≥ 1:80 and/or anti-dsDNA antibodies ≥ 30 IU/mL), of which ≥ 1 test result had to be obtained during screening. The study entry criteria were identical to those in BLISS-52 (17 (link)). BLISS-76 enrolled patients from Europe and North/Central America (136 centers in 19 countries). A stable treatment regimen was required for ≥ 30 days before the first study dose; stable treatment could include prednisone (or equivalent) alone (7.5 to 40 mg/d) or combined (0 to 40 mg/d) with AM drugs, nonsteroidal anti-inflammatory drugs, and/or IS therapies. Exclusion criteria included serious intercurrent illness, severe active lupus nephritis, severe central nervous system manifestations, and pregnancy. Prior treatment with a B-cell–targeted therapy was exclusionary, as was any investigational biologic agent within 1 year of screening or investigational nonbiologic agent within 60 days. Additional medication exclusions included IV cyclophosphamide within 6 months, and a tumor necrosis factor inhibitor, anakinra, IV Ig, prednisone > 100 mg/d, or plasmapheresis within 3 months of screening, as well as immunization with a live vaccine within 1 month. Each site was required to obtain ethics committee/institutional review board approval of the final study protocol. Patients’ rights, safety, and well-being were protected based on the principles of the Declaration of Helsinki. Informed consent was obtained from each patient prior to study screening. The first patient was randomized in February 2007, and follow-up of the last patient was completed in March 2010.
Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzová D., Sanchez-Guerrero J., Schwarting A., Merrill J.T., Chatham W.W., Stohl W., Ginzler E.M., Hough D.R., Zhong Z.J., Freimuth W, & van Vollenhoven R.F. (2011). A Phase 3, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits BLyS, in Patients With Systemic Lupus Erythematosus. Arthritis and rheumatism, 63(12), 3918-3930.
Publication 2011
Anakinra Anti-dsDNA antibody Anti-Inflammatory Agents, Non-Steroidal Biological Factors Cell Therapy Cyclophosphamide Diagnosis DNA, Double-Stranded Ethics Committees Ethics Committees, Research Immunization Institutional Ethics Committees Lupus Nephritis Patients Pharmaceutical Preparations Plasmapheresis Prednisone Pregnancy Safety Treatment Protocols Tumor Necrosis Factor Inhibitors Vaccines, Attenuated
3
RA Treatment Recommendations Literature Review
Literature searches for both DMARDs and biologics relied predominantly on PubMed searches) with medical subject headings (MeSH) and relevant keywords similar to those used for the 2008 ACR RA recommendations (see Appendices 1 and 2). We included randomized clinical trials (RCTs), controlled clinical trials (CCTs), quasi-experimental designs, cohort studies (prospective or retrospective), and case-control studies, with no restrictions on sample size. More details about inclusion criteria are listed below and in Appendix 3.
The 2008 recommendations were based on a literature search that ended on February 14, 2007. The literature search end date for the 2012 Update was February 26, 2010 for the efficacy and safety studies and September 22, 2010 for additional qualitative reviews related to TB screening, immunization and hepatitis (similar to the 2008 methodology). Studies published subsequent to that date were not included.
For biologics, we also reviewed the Cochrane systematic reviews and overviews (published and in press) in the Cochrane Database of Systematic Reviews to identify additional studies (5 (link)–8 ) and further supplemented by hand-checking the bibliographies of all included articles. Finally, the CEP and TFP confirmed that relevant literature was included for evidence synthesis. Unless they were identified by the literature search and met the article inclusion criteria (see Appendix 3), we did not review any unpublished data from product manufacturers, investigators, or the Food and Drug Administration (FDA) Adverse Event Reporting System.
We searched the literature for the eight DMARDs and nine biologics most commonly used for the treatment of RA. Literature was searched for eight DMARDS including azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, minocycline, organic gold compounds and sulfasalazine. As in 2008, azathioprine, cyclosporine and gold were not included in the recommendations based on infrequent use and lack of new data (Table 1). Literature was searched for nine biologics including abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab and tocilizumab; anakinra was not included in the recommendations due to infrequent use and lack of new data. Details of the bibliographic search strategy are listed in Appendix 1.
Singh J.A., Furst D.E., Bharat A., Curtis J.R., Kavanaugh A.F., Kremer J.M., Moreland L., O’Dell J., Winthrop K., Beukelman T., Bridges S.L., Chatham W.W., Paulus H., Suarez-Almazor M., Bombardier C., Dougados M., Khanna D., King C., Leong A., Matteson E.L., Schousboe J.T., Moynihan E., Kolba K., Jain A., Volkmann E.R., Agrawal H., Bae S., Mudano A., Patkar N.M, & Saag K.G. (2012). 2012 Update of the 2008 American College of Rheumatology (ACR) Recommendations for the use of Disease-Modifying Anti-Rheumatic Drugs and Biologics in the treatment of Rheumatoid Arthritis (RA). Arthritis care & research, 64(5), 625-639.
Publication 2012
Abatacept Adalimumab Anabolism Anakinra Antirheumatic Drugs, Disease-Modifying Azathioprine Biological Factors Certolizumab Pegol Cyclosporine Etanercept Gold Gold Compounds golimumab Hepatitis A Hydroxychloroquine Immunization Infliximab Leflunomide Methotrexate Minocycline Organic Chemicals Rituximab Safety Sulfasalazine tocilizumab
4
Measuring DMARD Utilization in RA Patients
The National Committee for Quality Assurance’s HEDIS RA measure aimed to assess “whether patients diagnosed with RA have had at least one ambulatory prescription dispensed for a DMARD [during the measurement year].” Patients in the denominator for the measure (1) were continuously enrolled in a MMC plan during the measurement year (no more than one 45-day gap in enrollment allowed), (2) had both medical and pharmacy benefits, and (3) had at least 2 face-to-face physician encounters with different dates of service in an ambulatory or non-acute patient setting during the measurement year with any diagnosis of RA (ICD-9 codes 714.0, 714.1, 714.2, or 714.81). Patients were excluded from the measure if they were pregnant or carried a diagnosis of HIV during the measurement year. Accepted drugs included both traditional and biologic DMARDs: abatacept, adalimumab, anakinra, azathioprine, cyclophosphamide, cyclosporine, etanercept, gold, hydroxychloroquine, infliximab, leflunomide, methotrexate, minocycline, penicillamine, rituximab, staphylococcal protein A, and sulfasalazine. The numerator for the measure was a dichotomous measure of DMARD receipt (yes/no); the names of the specific DMARDs received were not recorded.
Schmajuk G., Trivedi A., Solomon D., Yelin E., Trupin L., Chakravarty E, & Yazdany J. (2011). Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA : the journal of the American Medical Association, 305(5), 480-486.
Publication 2011
Abatacept Adalimumab Anakinra Antirheumatic Drugs, Disease-Modifying Azathioprine Biopharmaceuticals Cyclophosphamide Cyclosporine Diagnosis Etanercept Gold Hydroxychloroquine Infliximab Leflunomide Methotrexate Minocycline Patients Penicillamine Pharmaceutical Preparations Physicians RCE1 protein, human Rituximab Staphylococcal Protein A Sulfasalazine
5
Preparation and Administration of CAWS Complex
The CAWS complex was prepared based upon established methods (Nagi-Miura et al., 2006 (link); Tada et al., 2008 (link)). In brief, C. albicans was grown in C-limiting media (pH 5.2 at 27°C) for 2 d. An equal volume of ethanol was added and allowed to stand overnight. The culture was centrifuged, and the pellet was dissolved in water. The complex was centrifuged, and the soluble fraction was mixed with an equal volume of ethanol and again allowed to stand overnight. The complex was centrifuged, and the pellet was dried in acetone. The resulting CAWS complex was dissolved in water and autoclaved before use. Mice were injected i.p. with 4 mg CAWS. Where indicated, mice received doses of 0.25 mg anti–GM-CSF mAb (22E9.11) or rat IgG2a isotype control antibody (WEHI antibody facility), anti–GM-CSF receptor α mAb (CAM-3003; Greven et al., 2015 (link)), mouse IgG isotype control (MedImmune), or Anakinra i.p. three times weekly after CAWS challenge.
Stock A.T., Hansen J.A., Sleeman M.A., McKenzie B.S, & Wicks I.P. (2016). GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease. The Journal of Experimental Medicine, 213(10), 1983-1998.
Publication 2016
Acetone Anakinra CAM-3003 Ethanol Granulocyte-Macrophage Colony-Stimulating Factor IgG2A Immunoglobulin Isotypes Immunoglobulins Mice, House Receptors, Granulocyte-Macrophage Colony-Stimulating Factor

Most recents protocols related to «Anakinra»

1
Priming Neural Cells for DDD Modeling
NCS were formed in 96 well plates in NC differentiation medium (composition in Supplementary Material) for 3 days (Gryadunova et al., 2021 (link)) with/without GDF-5 (100 ng/mL), IL-1Ra (500 ng/mL) or the combination of both drugs. Then, the drugs were removed. Preconditioned NCS were either placed directly in DDD-mimicking condition (composition in Supplementary Material) for further 7 days and analyzed (chapter 4.3.2), or introduced into the NP microtissues (NPµT) model (see 4.3.3).
Kasamkattil J., Gryadunova A., Schmid R., Gay-Dujak M.H., Dasen B., Hilpert M., Pelttari K., Martin I., Schären S., Barbero A., Krupkova O, & Mehrkens A. (2023). Human 3D nucleus pulposus microtissue model to evaluate the potential of pre-conditioned nasal chondrocytes for the repair of degenerated intervertebral disc. Frontiers in Bioengineering and Biotechnology, 11, 1119009.
Full text: Click here
Publication 2023
Anakinra Drug Combinations Growth Differentiation Factor 5 Pharmaceutical Preparations
2
Subcutaneous Ccl2 Constructs for Serum-Induced Arthritis
All procedures were approved by IACUC at Washington University in St. Louis. Ccl2-Luc constructs were injected subcutaneously into C57BL/6 male and female mice. The rods were briefly washed in 37 °C phosphate buffered saline then aspirated using a 10 mL lure lock syringe with a sterilized 12-gauge stainless steel blunt needle. A small subcutaneous incision was made on the dorsal aspect of the mouse, the construct was delivered with the 12-gauge blunt needle, and the small incision was sutured closed with one suture and Vetbond skin glue (3M, St. Paul, MN, USA).
Serum transfer arthritis (STA) flare was induced at 1 week, 10 weeks (2.5 months), and 28-weeks (6 months) post-implantation with 175 µL of K/BxN serum delivered by retroorbital injection [32 (link),33 (link),34 (link)]. Ccl2-IL1Ra rod constructs were implanted subcutaneously using the blunt needle approach on the dorsal aspect of C57BL/6 mice (n = 3/treatment group). Control animals received either Ccl2-Luc constructs or no treatment. Disease activity (Clinical Score and Ankle Thickness) were assessed daily for 1 week.
As previously described [6 (link)], disease activity (clinical score and ankle thickness) and pain sensitivity (algometry and Electronic Von Frey) were assessed daily. Mice were then sacrificed, and serum and paws were collected for analysis. The severity of disease, termed clinical score, is assigned between 0–3 (0 = no swelling or erythema, 1 = slight swelling or erythema, 2 = moderate erythema and swelling in multiple digits or entire paw, 3 = pronounced erythema and swelling of entire paw; maximum total score of 12) [35 (link)]. Digital dial calipers were used to determine ankle thickness daily, which was subtracted from the thickness measured at day zero, on both hind paws [6 (link)]. These two values were averaged each day and reported as ankle thickness.
Collins K.H., Pferdehirt L., Saleh L.S., Savadipour A., Springer L.E., Lenz K.L., Thompson DM J.r., Oswald S.J., Pham C.T, & Guilak F. (2023). Hydrogel Encapsulation of Genome-Engineered Stem Cells for Long-Term Self-Regulating Anti-Cytokine Therapy. Gels, 9(2), 169.
Full text: Click here
Publication 2023
allobarbital Anakinra Animals Ankle Arthritis CCL2 protein, human Erythema Fingers Institutional Animal Care and Use Committees Males Mice, Inbred C57BL Mus Needles Ovum Implantation Phosphates Saline Solution Serum Skin Stainless Steel Sutures Syringes Woman
3
Comprehensive ALPS Patient Protocol
Patients were defined as ALPS definitive and probable according to the criteria established by the NIH in 2009.2 (link) (Table 1) Demographic data, clinical findings, biochemical markers (vitamin B12, interleukin 10 and interleukin 18, sFASL, immunoglobulins serum level, lymphocyte subsets analysis including CD3+CD4-CD8- TCR alfabeta+, named DNT cells), autoimmune markers (antiplatelet and antineutrophil indirect antibodies, direct and indirect Coombs test, antinuclear antibodies [ANA], extractable nuclear antigen antibodies, antismooth muscle antibody [ASMA], anti double-stranded DNA [anti-dsDNA] antibodies, antiglyadin, antitransglutaminase, antiendomysium, and antithyroglobulin antibodies) were entered into an electronic national ALPS database (ALPS Italian Network) (Tables 4 and 5).
All the information were retrieved from the medical records of patients after informed consent according to the Helsinki declaration of principles. Patients were referred at the ALPS Italian network through the AIEOP (Italian Pediatric Hemato-Oncology Association) centers.
Response to therapy was evaluated after at least 4–6 weeks of drug administration for each of the following clinical symptoms: cytopenia, lymphoproliferation, fever, or other autoimmune symptoms and scored as complete (CR), partial (PR), or nonresponse (NR) (See for further detail the footnotes of Table 6). In keeping with the response criteria from our previous publication,19 (link) a patient was considered as complete responder if all the aforementioned clinical symptoms disappeared/normalized 4–6 weeks after treatment start. A patient was considered as partial responder if at least one of the aforementioned clinical symptom improved/normalized 4–6 weeks after treatment start. A patient was considered as nonresponder if none of the above symptoms improved/normalized 4–6 weeks after treatment start.
First-line treatment was steroids or intravenous immunoglobulins, whereas the second-line was MMF or rapamycin. Further lines of treatment included: Rituximab plus MMF or rapamycin, anakinra, cyclosporine A, eltrombopag or Nplate (whenever cytopenia was the dominating sign) either alone or in combination with MMF or rapamycin.
Palmisani E., Miano M., Grossi A., Lanciotti M., Lupia M., Terranova P., Ceccherini I., Montanari E., Calvillo M., Pierri F., Micalizzi C., Maggiore R., Guardo D., Zanardi S., Facchini E., Maggio A., Mastrodicasa E., Corti P., Russo G., Pillon M., Farruggia P., Cesaro S., Barone A., Tosetti F., Ramenghi U., Crescenzio N., Bleesing J., Dufour C, & Fioredda F. (2023). Autoimmune Lymphoproliferative Syndrome (ALPS) Disease and ALPS Phenotype: Are They Two Distinct Entities?. HemaSphere, 7(3), e845.
Publication 2023
Aftercare Anakinra Anti-dsDNA antibody anti-thyroglobulin antibody Antibodies Antibodies, Antinuclear Autoimmune Lymphoproliferative Syndrome Cells Cobalamins Cyclosporine eltrombopag Extractable Nuclear Antigens Fever Immunoglobulins Indirect Coombs Test Interleukin-10 Interleukin-18 Intravenous Immunoglobulins Muscle Tissue myasthenia gravis anti-skeletal muscle antibody Neoplasms Nplate Patients Rituximab Serum Signs and Symptoms Sirolimus Steroids
4
Skin Surface Biomarkers Evaluation
Swab samples, a noninvasive method for skin surface evaluation, of 29 subjects were collected on both cheeks on D0 and D28 and in D84 only on the side of the face treated with M89PF. After the zone of interest and size were defined, a first swab previously dampened in the cocktail solution was rubbed onto the surface of interest for 45 seconds. Then, the same step was performed with a second swab previously dampened in the cocktail solution. Both swabs were introduced into a sample tube and stored at −20°C.
For sample extraction, each cotton bud was removed from its stick and placed into another 0.5mL sample tube drilled at the bottom itself and introduced into a 2 mL sample tube. The content was centrifuged for 3 min at 18,000 g at 4°C. The liquid obtained was collected for biochemical exploration.
The IL-8, IL-1alpha and IL1Ra assays were performed by Elisa (R&D Systems Inc., Minneapolis, MN, USA). A plate with a monoclonal antibody respectively specific for IL-8, IL-1α or IL1RA was prepared. Then, the sample of interest was deposited in order to bind to the antibody and to add a polyclonal antibody recognizing the antigen. A secondary antibody bound to the enzyme was added to convert it into a detectable entity (450 nm) directly proportional to the amount of IL-8, IL-1α or IL1RA.
The PGE2 assay, to test the COX-2 (Cyclo-oxygenase-2) activity, was carried out by Elisa (R&D Systems Inc., Minneapolis, MN, USA). A plate with anti-mouse IgG antibodies attached was prepared. A mixture of labeled antigens (alkaline phosphatase conjugated-PGE2) and antigens to be assayed (sample) were deposited on the plate. The Prostaglandin E2 antibody and substrate were then added and the enzymatic reactivity converted to a detectable entity (450 nm) inversely proportional to the amount of PGE2.
The Catalase activity was measured by enzyme kit (R&D Systems Inc., Minneapolis, MN, USA).
This method consists of measuring the residual content of hydrogen peroxide (H2O2) following the catalase action, which induced the fluorescence of resorufin. This is an indirect assay of hydrogen peroxide. The resorufin intensity is inversely proportional to the activity of catalase.
SOD activity was tested by enzyme kit (R&D Systems Inc., Minneapolis, MN, USA).
SOD catalyzes the conversion reaction of O2- into hydrogen peroxide and oxygen. These superoxide ions are produced by the conversion of xanthine to hydrogen peroxide and catalyze the WST-1 conversion reaction to produce a coloration detected at 450 nm.
Valpaços C., Leclerc-Mercier S., Lopes L., Svoboda D., Miranda D., Correia P., Junior J., Fernandes E., Francois-Newton V., Mandary M.B., Gueniche A., Tan J, & Kerob D. (2023). Benefits of the Dermocosmetic Mineral 89 Probiotic Fractions Adjunct to Topical Retinoids for Anti-Aging Benefits. Clinical, Cosmetic and Investigational Dermatology, 16, 375-385.
Publication 2023
Alkaline Phosphatase Anakinra anti-IgG Antibodies Antigens Biological Assay Catalase Catalysis Cheek Conversion Disorder Dinoprostone Enzyme-Linked Immunosorbent Assay Enzymes Face Fluorescence Gossypium IL1A protein, human Immunoglobulins Ions Monoclonal Antibodies Mus Oxygen Peroxide, Hydrogen PTGS2 protein, human resorufin Skin Superoxides Xanthine
5
Investigating Anti-Viral Interventions
The following treatment regimens were used in this study: siRNA (corresponding Dharmacon siGENOMESMARTpool): 1 nM/mouse, hydrodynamic i.v., −1 or −2 dpi, Poly I:C (Invivogen): 100 µg/mouse, hydrodynamic i.v., Mammalian expression plasmids: 10 µg/ mouse, Anakinra: 10 mg/kg, i.v., −1,0,1 dpi, Disulfiram (Sigma-Aldrich): 50 mg/kg in sesame oil, i.p.
Marques-da-Silva C., Poudel B., Baptista R.P., Peissig K., Hancox L.S., Shiau J.C., Pewe L.L., Shears M.J., Kanneganti T.D., Sinnis P., Kyle D.E., Gurung P., Harty J.T, & Kurup S.P. (2023). AIM2 sensors mediate immunity to Plasmodium infection in hepatocytes. Proceedings of the National Academy of Sciences of the United States of America, 120(2), e2210181120.
Publication 2023
Anakinra Disulfiram Hydrodynamics Mammals Mus Plasmids Poly I-C RNA, Small Interfering Sesame Oil Treatment Protocols

Top products related to «Anakinra»

1
Anakinra by Amgen
Sourced in United States
Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist. It is a laboratory equipment product manufactured by Amgen.
2
Anakinra by BioVitrum
Sourced in Sweden
Anakinra is a recombinant form of the human interleukin-1 receptor antagonist (IL-1Ra) protein. It functions to competitively inhibit the binding of interleukin-1 (IL-1) to the IL-1 type I receptor, thereby reducing the inflammatory response.
3
Kineret by BioVitrum
Sourced in Sweden
Kineret is a laboratory equipment product used for the detection and analysis of specific proteins or other biomolecules. It is a versatile tool that can be utilized in a variety of research and clinical applications.
4
Kineret by Amgen
Sourced in United States
Kineret is a laboratory equipment product used for protein purification and analysis. It is a device designed to isolate and concentrate specific proteins from complex biological samples. The core function of Kineret is to facilitate the separation, purification, and quantification of target proteins for research and diagnostic applications.
5
Il 1ra by R&D Systems
Sourced in United States, China, United Kingdom
IL-1Ra is a recombinant human Interleukin-1 Receptor Antagonist protein. It functions as a naturally occurring inhibitor of the pro-inflammatory cytokine Interleukin-1.
6
Il 1β by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, Austria, Italy, France, Japan, Canada, Sweden, Switzerland, Sao Tome and Principe, Israel
IL-1β is a lab equipment product that measures the levels of interleukin-1 beta, a pro-inflammatory cytokine, in biological samples. It is used for research purposes to quantify IL-1β expression and activity.
7
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
8
Anakinra by MedChemExpress
Sourced in United States
Anakinra is a laboratory equipment product manufactured by MedChemExpress. It is used for the detection and quantification of the interleukin-1 receptor antagonist (IL-1Ra) protein.
9
Anakinra by R&D Systems
Sourced in United States
Anakinra is a recombinant, non-glycosylated human interleukin-1 receptor antagonist (IL-1ra) protein. It is used for in vitro research purposes.
10
Mcc950 by Merck Group
Sourced in United States, United Kingdom, Germany, China
MCC950 is a laboratory equipment product manufactured by Merck Group. It is a versatile tool used for various scientific applications. The core function of MCC950 is to provide a controlled environment for experiments and analyses. Detailed product specifications and intended use are not available in this factual and unbiased description.

More about "Anakinra"

Anakinra, also known as Kineret, is a recombinant human interleukin-1 receptor antagonist (IL-1Ra) used to treat rheumatoid arthritis and other inflammatory conditions.
It works by blocking the effects of interleukin-1 (IL-1β), a key mediator of the body's response to infection, injury, and autoimmune disorders.
Anakinra has been shown to reduce symptoms and improve physical function in patients with moderate-to-severe rheumatoid arthritis.
It is typically administered by daily subcutaneous injection and is generally well-tolerated, although some patients may experience injection-site reactions or an increased risk of infection.
In addition to rheumatoid arthritis, Anakinra has been studied for the treatment of other inflammatory conditions, such as gout, periodic fever syndromes, and certain types of autoinflammatory disorders.
Researchers are also exploring the potential use of Anakinra in combination with other therapies, such as DMSO and MCC950, to enhance its efficacy and reduce side effects.
PubCompare.ai's AI-powered protocol comparison tool can help optimize your Anakinra research by allowing you to easily locate and identify the best protocols and products from literature, pre-prints, and patents.
This can improve the reproducibility of your Anakinra studies and help you make more informed decisions about your research approach.